



HUTCHISON CHINA MEDITECH LIMITED

Directors' Share Dealing

London: Tuesday, August 15, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-

- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated ("PCA") with Mr To, purchased a total of 3,188 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US\$1.00 each in the capital of Chi-Med) on August 14, 2017 at a price of US\$24.47 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the "DDT") which has been established for the benefit of Mr To's family members, of which Mr To is the settlor; and
- (b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,001 ADSs at an average price of US\$25.67 per ADS on August 10 and 11, 2017.

Following the above purchases, (i) Mr To is interested in 113,589 ADSs (in DDT and Wencheng Trust of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 90,664 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

(a) Dynamic Drive Limited

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Dynamic Drive Limited
2	Reason for the notification	
a)	Position/status	Person closely associated with Mr Simon To, Executive Director and Chairman. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust which has been established for the benefit of Mr To's family members, of which Mr To is the settlor.
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Hutchison China MediTech Limited
b)	LEI	2138006X34YDQ6OBYE79

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US\$1.00 ADS ISIN: US44842L1035	
b)	Nature of the transaction	Acquisition of 3,188 ADSs in the name of Dynamic Drive Limited which holds the ADSs for a family trust (Dynamic Drive Trust) of which Mr To is the settlor on August 14, 2017 at a price of US\$24.47 per ADS.	
c)	Price(s) and volume(s)		
		Price(s)	Volume(s)
		US\$24.47	3,188
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	2017-08-14	
f)	Place of the transaction	Nasdaq Stock Market	

(b) Ms Edith Shih

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Ms Edith Shih
2	Reason for the notification	
a)	Position/status	Non-executive Director and Company Secretary
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Hutchison China MediTech Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US\$1.00 ADS ISIN: US44842L1035	
b)	Nature of the transaction	Acquisition of 5,001 ADSs on August 10 and 11, 2017 at an average price of US\$25.67 per ADS.	
c)	Price(s) and volume(s)		
		Price(s)	Volume(s)
		US\$25.60	1,904
		US\$25.58	96
		US\$25.70	1,900
		US\$25.69	100
		US\$25.75	900
		US\$25.74	100
		US\$25.40	1
d)	Aggregated information - Aggregated volume - Price	Aggregated volume: 5,001 ADSs Price information: US\$25.67	
e)	Date of the transaction	2017-08-10 – acquisition of 5,000 ADSs 2017-08-11 – acquisition of one ADS	
f)	Place of the transaction	Nasdaq Stock Market	

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 0001). For more information, please visit: www.chi-med.com.

CONTACTS

Investor Enquiries

Mark Lee, +852 2121 8200
SVP Corporate Finance & Development

U.K. & International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media Enquiries

Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com

Investor Relations

Matt Beck, The Trout Group
David Dible, Citigate Dewe Rogerson

+1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
+44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts

+44 (20) 7886 2500